跳至主要内容
临床试验/NCT04823715
NCT04823715已完成不适用

Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison

Hospices Civils de Lyon1 个研究点 分布在 1 个国家目标入组 163 人开始时间: 2020年10月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
163
试验地点
1
主要终点
Disease-free survival of the patient after start of treatment

研究概览

简要总结

Patients with non-metastatic unresectable hepatocellular carcinoma

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years of age
  • Histologically proven hepatocellular carcinoma or proven according to radiological and biochemical criteria (EASL-AASLD) in cirrhotic patients
  • Child-Pugh class A
  • Absence of truncular or lobar portal vein invasion, or suprahepatic vein invasion

排除标准

  • Uncontrolled replication of hepatitis B virus
  • Transplanted liver
  • Previous abdominal irradiation
  • Previous treatment of HCC with systemic therapy, or with surgical resection in the 2 previous years
  • Metastatic illness

结局指标

主要结局

Disease-free survival of the patient after start of treatment

时间窗: Within 10 years after the treatment (surgical resection or TACE)

Disease-Free Survival (DFS) defined as the time (in months) between the treatment (surgical resection or TACE) and the diagnostic of local, locoregional or distant recurrence, or date of death from any cause; patients who are alive or lost to follow-up at the time of the analysis will be censored on the last follow-up date; patients who have received a liver transplant for non-carcinologic reason will be censored on the date of transplantation.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验